A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans. © 2024 Fortune Media IP Limited. All Rights ...

Copyright 2025 The Associated Press. All Rights Reserved. A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad “economic and societal impact” because of “noticeable shifts in dietary behavior.” The study ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in overweight/obese ...

Semaglutide was originally designed to tackle Type 2 diabetes but was repurposed for obesity and trials showed its stronger dose form, branded as Wegovy, could help users lose 15% of their body ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and development efforts. Historically, oncology and immunology were the ...